It is more probable that PBT2 will be part of the solution, hopefully the first part. A combination of therapeutics is the more probable outcome to a neurodegenerative disease solution, given the unknowns. Valuation is subjective to the complimentary or competing compound of the potential acquirer.
If PBT2 is standalone therapy upgrade your wine preferences.
your either in or out, page-43
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $11.18K | 3.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 52064257 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126697935 | 22 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |